过去一年中添加的文章，按日期排序
Enhancing Pancreatic Ductal Adenocarcinoma Immunotherapy Through the Inhibition of Focal Adhesion Kinase
A Wu - jmsgr.tamhsc.edu
26 天前 - … Objective: In this review, we determined the effectiveness of combining a FAK
inhibitor with various PDAC therapies to assess the effect that stromal targeting has on enhancing …
inhibitor with various PDAC therapies to assess the effect that stromal targeting has on enhancing …
[HTML][HTML] Network pharmacology-and cell-based assessments identify the FAK/Src pathway as a molecular target for the antimetastatic effect of momordin Ic against …
P Pocasap, A Prawan, S Kongpetch, L Senggunprai - Heliyon, 2024 - cell.com
35 天前 - … MIc mitigates metastatic behaviours and suppresses key pathways, offering a
promising avenue for future therapeutic strategies against this aggressive cancer. …
promising avenue for future therapeutic strategies against this aggressive cancer. …
… -mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer
A Yoshimura, M Horinaka, T Yaoi, H Ono, K Itoh… - … Journal of Cancer, 2024 - nature.com
38 天前 - … Recent therapeutic strategies for KRAS-mutated cancers that inhibit the MAPK
pathway … after avutometinib treatment and synergy between avutometinib and FAK inhibitor, …
pathway … after avutometinib treatment and synergy between avutometinib and FAK inhibitor, …
Dual targeting of αv and α5β1 integrins in triple-negative breast cancer (TNBC).
F Song, K Do, DEC Fein, N Jahanseir, R Joshi… - 2024 - ascopubs.org
40 天前 - … The impact of integrin blockade on nuclear localization of basal markers including
FAK, … /αvβ1 defines a novel therapeutic strategy with a distinct mechanism of action for further …
FAK, … /αvβ1 defines a novel therapeutic strategy with a distinct mechanism of action for further …
FBXO32 Stimulates Protein Synthesis to Drive Pancreatic Cancer Progression and Metastasis
D Su, R Wang, G Chen, C Ding, Y Liu, JI Tao, Y Wang… - Cancer Research, 2024 - AACR
47 天前 - … underlying mechanisms responsible for PDAC progression is required to identify
improved therapeutic strategies… inhibition of FAK by defactinib, an FDA-approved FAK inhibitor, …
improved therapeutic strategies… inhibition of FAK by defactinib, an FDA-approved FAK inhibitor, …
Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders
M Yang, H Xiang, G Luo - Biochemical Pharmacology, 2024 - Elsevier
72 天前 - … Proteolysis-targeting chimeras (PROTACs) are a promising therapeutic strategy
for cancer, first proposed by the laboratories of Crews and Deshaies in 2001 [109]. PROTAC …
for cancer, first proposed by the laboratories of Crews and Deshaies in 2001 [109]. PROTAC …
Prospects of focal adhesion kinase inhibitors as a cancer therapy in preclinical and early phase study
J Gao, J Cheng, W Xie, P Zhang, X Liu… - Expert Opinion on …, 2024 - Taylor & Francis
72 天前 - … This paper aims to summarize the molecular mechanisms underlying FAK’s
involvement in tumorigenesis and progression. Encouraging results have emerged from ongoing …
involvement in tumorigenesis and progression. Encouraging results have emerged from ongoing …
[PDF][PDF] Mechanistic Study of CRABP2: Accelerating Lung Cancer Migration and Metastasis through Regulation of the ROS/Src Signaling Pathway
G Yang, H Liu, Q Yin, Z Tian - … Therapies in Health and …, 2024 - alternative-therapies.com
87 天前 - … -FAK levels, shedding light on the underlying mechanism. CRABP2’s influence on
lung … cancer, offering a theoretical framework for advancing lung cancer treatment strategies. …
lung … cancer, offering a theoretical framework for advancing lung cancer treatment strategies. …
[HTML][HTML] The dysadherin/FAK axis promotes individual cell migration in colon cancer
CJ Lee, TY Jang, JH Kim, S Lim, S Lee… - International Journal of …, 2024 - ncbi.nlm.nih.gov
91 天前 - … Overall, this study illuminates the role of dysadherin in modulating cancer cell … via
FAK signaling, indicating that targeting dysadherin may be a potential therapeutic strategy for …
FAK signaling, indicating that targeting dysadherin may be a potential therapeutic strategy for …
HMGB2 Release Promotes Pulmonary Hypertension and Predicts Severity and Mortality of Patients With Pulmonary Arterial Hypertension
D Kong, J Liu, J Lu, C Zeng, H Chen… - … and Vascular Biology, 2024 - Am Heart Assoc
95 天前 - … targeting HMGB2 might be a novel therapeutic strategy for treating PH. Serum HMGB2
… with the presence or absence of buffer or FAK inhibitor (FAK-I). L, Quantification of p-YAP …
… with the presence or absence of buffer or FAK inhibitor (FAK-I). L, Quantification of p-YAP …